Potent Ruthenium–Ferrocene Bimetallic Antitumor Antiangiogenic Agent That Circumvents Platinum Resistance: From Synthesis and Mechanistic Studies to <i>In Vivo</i> Evaluation in Zebrafish
作者:Manikandan M、Shubhankar Gadre、Sushanta Chhatar、Gourav Chakraborty、Naushad Ahmed、Chinmoy Patra、Malay Patra
DOI:10.1021/acs.jmedchem.2c01174
日期:2022.12.22
in cancer cells and dose-limiting side effects severely limit the widespread use of platinum (Pt) anticancer drugs. Multi-action hybrid anticancer agents that are constructed by merging two or more pharmacophores offer the prospect of circumventing issues of Pt drugs. Herein, we report the design, synthesis, and in-depth biological evaluation of a ruthenium–ferrocene (Ru-Fc) bimetallic agent [(η6-p-cymene)Ru(1
癌细胞耐药性的出现和剂量限制性副作用严重限制了铂(Pt)抗癌药物的广泛使用。通过合并两个或多个药效基团构建的多作用混合抗癌剂为规避铂类药物的问题提供了前景。在此,我们报告了钌-二茂铁(Ru-Fc)双金属剂[(η 6 - p -cymene)Ru(1,1,1-triflu-4-oxo- 4-二茂铁基-丁-2-烯-2-油酸)Cl]及其五种类似物。除了水化/阴离子化学之外,我们还评估了体外抗肿瘤效力、Pt 交叉耐药性和体内抗血管生成特性。进行结构活性分析以了解Fc、CF 3和p-伞花烃基团对Ru-Fc杂合体的抗癌效力的影响。最后,除了评估细胞摄取和细胞内分布外,我们还证明Ru-Fc杂合体与亲核生物分子结合并产生活性氧,从而导致线粒体功能障碍并诱导内质网应激,从而导致聚(ADP-核糖)聚合酶介导的坏死性细胞死亡。